Choosing the best path to patients: how to decide between in-house and outsourced iPSC therapy development and manufacturing

Laura Koivusalo, Anni Mörö, Ross Macdonald

11 March 2025

Commentary

Personalization in advanced cellular ImmunoTherapeutics: activities in Ireland

Athanasios Mantalaris, Nicki Panoskaltsis, Fiona Killard

13 January 2025

Commentary

De-risking pluripotent stem cell therapies

Stephen Sullivan, Ricardo Baptista

18 June 2024

Commentary

Unlocking the full potential of human induced pluripotent stem cells from haplo-selected cord blood samples—the how and the why

B Aran, D Morrow, E Rodriguez et al

14 February 2024

Commentary

Innovation in cryopreservation & cold chain management

Barry Fuller, Roland Fleck, Glyn Stacey

22 November 2023

Commentary

Cell and gene therapy commercial off-the-shelf software components

Parris Farr

23 August 2023

Commentary

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

G Thakur, S Mink, H Bak et al

06 June 2023

Commentary

Alloplex Biotherapeutic’s SUPLEXA cells represent a new type of autologous adoptive cellular therapy for cancer

Frank Borriello, James A Lederer

25 April 2023

Commentary

Overcoming challenges to CAR-T cell therapies in India

A Uppal, R Chakrabarti, N Chirmule et al

08 March 2023

Commentary

Cell therapy 101 (part 1)Challenges of early clinical development: a ‘thumbnail sketch’

Michael D Leek

29 November 2022

Commentary

Why we need a revolution for personalized cell therapies

S Steiner, B Gilgen, E Pernot et al

06 July 2022

Commentary

COVID-19: how is the pandemic changing the vaccines space?

Nicholas Jackson

24 May 2022

Commentary

Regulatory & supply chain implications for plasmids as critical starting materials in the manufacture of viral vector gene therapy products

M Gosse, C Jones, D Jesus et al

08 March 2022

Commentary

Challenges in qualification & management of raw materials in advanced therapy medicinal products

Shok Ping Lim, Sakina Gooljar

04 March 2022

Commentary

The UK’s emerging regulatory framework for point-of-care manufacture: insights from a workshop on advanced therapies

E Bicudo, I Brass, P Carmichael et al

30 September 2021

Commentary

Outcomes from a cell viability workshop: fit-for-purpose considerations for cell viability measurements for cellular therapeutic products

L Pierce, S Sarkar, L Li-Ying Chan et al

14 May 2021

Commentary

Finding quality in complexity: how cellular therapeutics are shifting analytical paradigms for clinical supply and product manufacturing

Vilma Jimenez Sabinina, Dominic Günter Hildebrand

13 May 2021

Commentary

Making the move from antibody therapeutics to gene therapy: applicability of monoclonal antibody learnings to adeno-associated virus vector bioprocessing

Andrew D Tustian

29 April 2021

Commentary

Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

David R Knop, PhD

29 April 2021

Commentary

Future-proofing cell therapy manufacturing capability: lessons from the NCI

Anthony Welch, Marc Ernstoff, Jason Yovandich

20 April 2021

Commentary

Master ATMP processes by controlling raw and starting material

Anne-Sophie Lebrun, Carmen Brenner

24 March 2021

Commentary